A new RNA‑editing technology, termed AIM (Adjustable RNA Information Manipulation), uses a single‑strand deaminase to enable controllable, site‑specific RNA editing, according to a Nature Biotechnology report. The platform delivers precise nucleotide conversions and adjustable editing windows, aiming to expand the toolkit for transient therapeutic edits and functional genomics. Authors demonstrated tunability and specificity across multiple targets in cellular systems, positioning AIM as a potential approach for diseases amenable to RNA correction without altering genomic DNA. The study emphasized implications for therapeutic development where reversible or transient modulation of RNA is preferred.